SCHEMBL5062997

SCHEMBL5062997

CN(C)CCNc1ncc2cc(-c3ccc(F)c(NC(=O)Nc4cc(C(C)(C)C)nn4-c4cccc(CC(N)=O)c4)c3)c(=O)n(C)c2n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 20/20 0.52
RAF1 P04049 1/20 0.50
BRAF P15056 1/20 0.50
EPHB2 P29323 1/20 0.50
RET P07949 7/20 0.43
CDK8 P49336 7/20 0.43
PDGFRA P16234 6/20 0.43
PAK4 O96013 3/20 0.43
MAP4K5 Q9Y4K4 2/20 0.43
AURKB Q96GD4 1/20 0.43
CLK4 Q9HAZ1 1/20 0.43
TYRO3 Q06418 3/20 0.41
NTRK2 Q16620 3/20 0.41
TAOK1 Q7L7X3 3/20 0.41
PRKX P51817 2/20 0.41
ROCK1 Q13464 2/20 0.41
GRK5 P34947 2/20 0.41
PRKAA1 Q13131 1/20 0.41
PRKD3 O94806 3/20 0.41
LRRK2 Q5S007 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5065442 0.89 MAPK14 (0.57) MAPK14RAF1BRAFEPHB2RET
SCHEMBL4419974 0.87 BRAF (0.46) MAPK14RAF1BRAFMAPK13MAPK12
SCHEMBL5055112 0.82 MAPK14 (0.53) MAPK14RAF1BRAFMAPK9MAPK13
SCHEMBL4425259 0.81 MAPK14 (0.52) MAPK14RAF1BRAFMAPK13MAPK12
SCHEMBL4272187 0.80 BRAF (0.44) MAPK14RAF1BRAFPDGFRAABL1
SCHEMBL4563409 0.80 MAPK14 (0.53) MAPK14BRAFRETCDK8PDGFRA
SCHEMBL5061867 0.80 BRAF (0.58) MAPK14RAF1BRAFEPHB2RET
SCHEMBL5055067 0.80 BRAF (0.45) MAPK14RAF1BRAFCDK8MAPK9
SCHEMBL5065364 0.79 MAPK14 (0.53) MAPK14BRAFMAPK9MAPK13MAPK12
SCHEMBL5057688 0.79 FGFR1 (0.45) MAPK14RAF1BRAFPDGFRAABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PARMACEUTICALS, LLC (US) 2008-05-15 US claimed
US-8188113-B2 For example, 1-(5-(2-amino-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl)-2-fluorophenyl)-3-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies DECIPHERA PHARMACEUTICALS, INC. (US) 2012-05-29 US disclosed
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PARMACEUTICALS, LLC (US) 2008-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 MAPK14 240/4885RAF1 3/4885BRAF 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.